These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 4053009

  • 1. Tissue-specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine.
    Darnowski JW, Handschumacher RE.
    Cancer Res; 1985 Nov; 45(11 Pt 1):5364-8. PubMed ID: 4053009
    [Abstract] [Full Text] [Related]

  • 2. Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor.
    Pizzorno G, Yee L, Burtness BA, Marsh JC, Darnowski JW, Chu MY, Chu SH, Chu E, Leffert JJ, Handschumacher RE, Calabresi P.
    Clin Cancer Res; 1998 May; 4(5):1165-75. PubMed ID: 9607574
    [Abstract] [Full Text] [Related]

  • 3. Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine.
    Martin DS, Stolfi RL, Sawyer RC.
    Cancer Chemother Pharmacol; 1989 May; 24(1):9-14. PubMed ID: 2720896
    [Abstract] [Full Text] [Related]

  • 4. Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys: implications for chemotherapy.
    Sommadossi JP, Cretton EM, Kidd LB, McClure HM, Anderson DC, el Kouni MH.
    Cancer Chemother Pharmacol; 1995 May; 37(1-2):14-22. PubMed ID: 7497584
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. 19F NMR monitoring of in vivo tumor metabolism after biochemical modulation of 5-fluorouracil by the uridine phosphorylase inhibitor 5-benzylacyclouridine.
    Holland SK, Bergman AM, Zhao Y, Adams ER, Pizzorno G.
    Magn Reson Med; 1997 Dec; 38(6):907-16. PubMed ID: 9402191
    [Abstract] [Full Text] [Related]

  • 8. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
    Al Safarjalani ON, Rais R, Shi J, Schinazi RF, Naguib FN, el Kouni MH.
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
    [Abstract] [Full Text] [Related]

  • 9. Benzylacyclouridine. Pharmacokinetics, metabolism and biochemical effects in mice.
    Darnowski JW, Handschumacher RE.
    Biochem Pharmacol; 1988 Jul 01; 37(13):2613-8. PubMed ID: 3390221
    [Abstract] [Full Text] [Related]

  • 10. Species-dependent differences in the biochemical effects and metabolism of 5-benzylacyclouridine.
    Davis ST, Joyner SS, Chandrasurin P, Baccanari DP.
    Biochem Pharmacol; 1993 Jan 07; 45(1):173-81. PubMed ID: 8424810
    [Abstract] [Full Text] [Related]

  • 11. Effect of 5-benzylacyclouridine, a potent inhibitor of uridine phosphorylase, on the metabolism of circulating uridine by the isolated rat liver.
    Monks A, Ayers O, Cysyk RL.
    Biochem Pharmacol; 1983 Jul 01; 32(13):2003-9. PubMed ID: 6870929
    [Abstract] [Full Text] [Related]

  • 12. High-dose 5-fluorouracil with delayed uridine "rescue" in mice.
    Martin DS, Stolfi RL, Sawyer RC, Spiegelman S, Young CW.
    Cancer Res; 1982 Oct 01; 42(10):3964-70. PubMed ID: 7104997
    [Abstract] [Full Text] [Related]

  • 13. Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5-benzyloxybenzyluracil.
    Naguib FN, Hao SN, el Kouni MH.
    Cancer Res; 1994 Oct 01; 54(19):5166-70. PubMed ID: 7923135
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of nucleoside transport in murine lymphoma L5178Y cells and human erythrocytes by the uridine phosphorylase inhibitors 5-benzylacyclouridine and 5-benzyloxybenzylacyclouridine.
    Lee KH, el Kouni MH, Chu HS, Cha S.
    Cancer Res; 1984 Sep 01; 44(9):3744-8. PubMed ID: 6744292
    [Abstract] [Full Text] [Related]

  • 15. Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity.
    Al Safarjalani ON, Rais R, Naguib FN, el Kouni MH.
    Cancer Chemother Pharmacol; 2012 Jun 01; 69(6):1449-55. PubMed ID: 22373605
    [Abstract] [Full Text] [Related]

  • 16. Brequinar potentiates 5-fluorouracil antitumor activity in a murine model colon 38 tumor by tissue-specific modulation of uridine nucleotide pools.
    Pizzorno G, Wiegand RA, Lentz SK, Handschumacher RE.
    Cancer Res; 1992 Apr 01; 52(7):1660-5. PubMed ID: 1551097
    [Abstract] [Full Text] [Related]

  • 17. Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites.
    Peters GJ, van Groeningen CJ, Laurensse EJ, Lankelma J, Leyva A, Pinedo HM.
    Cancer Chemother Pharmacol; 1987 Apr 01; 20(2):101-8. PubMed ID: 3664929
    [Abstract] [Full Text] [Related]

  • 18. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
    Leyva A, van Groeningen CJ, Kraal I, Gall H, Peters GJ, Lankelma J, Pinedo HM.
    Cancer Res; 1984 Dec 01; 44(12 Pt 1):5928-33. PubMed ID: 6498850
    [Abstract] [Full Text] [Related]

  • 19. Benzylacyclouridine enhances 5-fluorouracil cytotoxicity against human prostate cancer cell lines.
    Yee LK, Chu E, Pan BC, Chu SH, Chen TM, Lipsky MH, Chu MY, Calabresi P.
    Pharmacology; 1998 Feb 01; 56(2):80-91. PubMed ID: 9494066
    [Abstract] [Full Text] [Related]

  • 20. 5-Fluorouracil enhances azidothymidine cytotoxicity: in vitro, in vivo, and biochemical studies.
    Brunetti I, Falcone A, Calabresi P, Goulette FA, Darnowski JW.
    Cancer Res; 1990 Jul 01; 50(13):4026-31. PubMed ID: 2354452
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.